Thursday, May 5, 2022 episode artwork

EPISODE · May 5, 2022 · 5 MIN

Thursday, May 5, 2022

from The Gist Healthcare Podcast

The FDA says there’s "no evidence" that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing scrutiny for its marketing and prescribing practices. And a Health Affairs study finds several physicians in insurers’ Medicaid networks aren’t seeing patients. Hosted on Acast. See acast.com/privacy for more information.

The FDA says there’s "no evidence" that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing scrutiny for its marketing and prescribing practices. And a Health Affairs study finds several physicians in insurers’ Medicaid networks aren’t seeing patients. Hosted on Acast. See acast.com/privacy for more information.

NOW PLAYING

Thursday, May 5, 2022

0:00 5:39

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Gist Healthcare Podcast?

This episode is 5 minutes long.

When was this The Gist Healthcare Podcast episode published?

This episode was published on May 5, 2022.

What is this episode about?

The FDA says there’s "no evidence" that doubling an individual’s dose of Paxlovid will reduce the return of COVID symptoms. Mental health telemedicine company Cerebral stops prescribing Adderall to new patients as the company faces increasing...

Can I download this The Gist Healthcare Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!